Ovid Therapeutics Inc. announced changes to its senior management team to focus the company resources and attention on its late stage pipeline. effective April 1, 2019 Amit Rakhit, M.D., MBA, is adding the role of Head of R&D to his current position as Chief Medical Officer, He will be responsible for all aspects of Ovid’s pipeline and development strategy. Matthew During, M.D., D.Sc., will transition out of his role as President and Chief Scientific Officer while becoming Chairman of the Company Scientific Advisory Board (SAB). As part of this transition, Dr. During has decided not to stand for reelection following his current term on Ovid Board of Directors.